Navigation Links
Peer-reviewed Article Reports ProImmune's Immune Formulation 200® Activates the Immune-Support Gene Nrf2.
Date:6/28/2012

(PRWEB) June 28, 2012

ProImmune's Immune Formulation 200® is able to potentiate Glutathione synthesis via the Pleiotropic Paradox, which utilizes the pleiotropic delivery system of the disulfide bond--L-Cystine--to carry L-Cysteine safely to cells,. Upon contact with epithelial cells, the L-Cystine is decoupled by the substrate specific enzyme thioltransferase, allowing L-Cysteine safely into cells to enter into the Glutathione Synthesis chain.

Dr. Albert Crum, a Harvard-trained scientist and CEO of The ProImmune Company, LLC, Rhinebeck (NY) is the inventor of Patent RE42,645E/RE39,734 and its Immune Formulation 200®. University research using Immune Formulation 200® provided by The ProImmune Company, LLC, has demonstrated that this novel Glutathione precursor’s immune support effects are unexpectedly wide-ranging.

The coupling of a thiol-disulfide compound is another safe physiological carrier system for L-Cysteine, because it holds the high oxidizability of L-Cysteine in abeyance ("on hold") until it is delivered to the intracellular milieu.

Metaphorically speaking, the Glutathione pathway of Immune Formulation 200® activates the immune system like a city power grid station which ignites or electrifies a city's lights. The Dietary Supplement Immune Formulation 200® is a strong support for the immune system in multiple ways.

Immune Formulation 200® works physiologically, both to raise bodily Glutathione levels and to activate Nrf2, while offering an inherently natural sweet taste without carbohydrates. Immune Formulation 200® (“F1”), a dietary supplement, is the patented precursor for the intracellular synthesis of Glutathione.

Specifically, research on Immune Formulation 200® provided by The ProImmune Company, L.L.C., has been conducted over several years by a team at Drew University of Medicine & Science, Los Angeles (CA). Other universities such as UCLA, University of California (Irvine), Los Angeles Biomedical Research Institute (Torrance CA), and University of Texas Southwestern (Dallas) are included among those conducting the basic research on Immune Formulation 200®. Research results began being published in 2008. Research studies of Immune Formulation 200® have pointed to the interrelationship between Glutathione repletion and activation of gene Nrf2.

Immune Formulation 200® is winning international consumer favor--for the value of its diversified immunological support and for its naturally sweet taste.

The study which associated Immune Formulation 200® with the activation of Nrf2 was supported by NIH-NCCR Accelerating Excellence in Translation Science Grant (U54 RR026138) and NIH-NIMHDP20MD00182.

© 2012 The ProImmune Company LLC

Read the full story at http://www.prweb.com/releases/2012/6/prweb9653539.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Nucleic Acids Research Journal Publishes Sapphire Energy Peer-Reviewed Research Paper on a Chloroplast Genome From Green Algae
2. Study improves understanding of surface molecules in controlling size of gold nanoparticles
3. Nanoparticles found in moon glass bubbles explain weird lunar soil behavior
4. Nanoparticles seen as artificial atoms
5. Exotic particles, chilled and trapped, form giant matter wave
6. A milestone in nanoparticle research: Nanoparticle test handbook sets the standards
7. Genesis Biopharma Mentioned Favorably in BioMedReports Article
8. Light touch keeps a grip on delicate nanoparticles
9. New technique uses electrons to map nanoparticle atomic structures
10. New measuring techniques can improve efficiency, safety of nanoparticles
11. Metal nanoparticles shine with customizable color
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Peer-reviewed Article Reports ProImmune's Immune Formulation 200® Activates the Immune-Support Gene Nrf2.
(Date:1/19/2017)... 19, 2017  Market Research Future has a half cooked research ... Biopsy is growing rapidly and expected to reach USD 450 Million ... ... Biopsy Market has been assessed as a swiftly growing market and ... in the coming future. There has been a tremendous growth in ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... for pharmaceutical research and development (R&D), today announced the launch of ... and interpretation for the rapidly evolving field of precision medicine. , ...
(Date:1/19/2017)... AquaBounty Technologies, Inc. (AIM: ABTU; NASDAQ: AQB), ... and a majority-owned subsidiary of Intrexon Corporation (NYSE: ... listing of its common shares on the NASDAQ Stock ... "AquaBounty,s listing on NASDAQ represents an important milestone ... the U.S. markets as we advance plans for commercial ...
(Date:1/19/2017)... ... January 19, 2017 , ... DaVita Clinical Research ... drug and device development, and Prism Clinical Research , a leader in ... Verified Clinical Trials (VCT) has been selected by both companies as ...
Breaking Biology Technology:
(Date:1/12/2017)... NEW YORK , Jan. 12, 2017  New research ... around the office of the future.  1,000 participants were simply ... last three months which we may consider standard issue.  Insights ... office of 2017 were also gathered from futurists and industry ... and Dr. James Canton .  Some ...
(Date:1/6/2017)... Calif. , Jan. 6, 2017  Privately-held ... safety studies in healthy volunteers of a novel ... to treat acute pancreatitis. Acute ... typically a mild disorder, but can be very ... failure and sepsis, where extended hospital stays, time ...
(Date:1/4/2017)... 4, 2017  CES 2017 – Valencell , ... today announced the launch of two new versions ... highly-accurate biometric sensor modules that incorporate the best ... and expertise. The two new designs include Benchmark ... hearables, and Benchmark BW2.0, a 2-LED version of ...
Breaking Biology News(10 mins):